Hemo Organic LimitedBSE: HEMORGANIC

Statement On Deviation(S) / Variation(S) In Utilization Of Proceeds Raised Through Preferential Issue Of Convertible Warrants, Pursuant To Regulation 32 Of SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations) For The Quarter Ended On September 3

· Issued by Hemo Organic Limited via BSE India

Filed with BSE · · 13 pages · English

Summary by 6ix AI

Hemo Organic Limited has submitted its un-audited financial results along with a limited review report for the quarter and half year ended on a specified date. The financial results were reviewed by the Audit Committee and approved by the Board of Directors during a meeting. The filing confirms that there were no deviations in the utilization of proceeds from a recent preferential issue of convertible warrants.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/statement-on-deviations-variations-in-utilization-of-proceeds-raised-through-preferential-issue-of-convertible-warrants-pursuant-to-regulation-32-of-sebi-lodr-regulations-2015-sebi-listing-regulations-for-the-quarter-ended-on-september-3

Please take note of the same and oblige. KAMESHWAR KAMESHWAR SINGH Vishwambar Kameshwar Singh Managing Director Mumbai – 400001. Ref: Scrip Code: 524590 | Scrip Symbol: HEMORGANIC | ISIN: INE422G01015 You are requested to kindly take the above information on record. VISHWAMBAR VISHWAMBAR KAMESHWAR SINGH MANAGING DIRECTOR STATEMENT OF DEVIATION OR VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE OF CON

Hemo Organic Limited on 6ix

Story so far

Earlier from Hemo Organic

All Hemo Organic news releases